PTO/S8/81 (11-04)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are requi

## POWER OF ATTORNEY **CORRESPONDENCE ADDRESS INDICATION FORM**

ired to respond to a collection of information unless it displays a valid QMB control number.				
Application Number	10659116			
Filing Date	09-10-2003			
First Named Inventor	Daniel M. Lafontaine			
Title	Cryoplasty Device and Method			
Art Unit	3739			
Examiner Name	Roy Dean Gibson			
Attorney Docket Number	1001.2573104			

I hereby revoke all previous powers of attorney given in the above-identified application.							
I hereby appoint:							
Practitioners associated with the Customer Number:	28075						
Practitioner(s) named below:							
Name	Registration Number						
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.							
Please recognize or change the correspondence address for the above-identified application to:  The address associated with the above-mentioned Customer Number:  OR  The address associated with Customer Number:							
Firm or Individual Name							
Address							
City	State Zip						
Country Telephone	Fax						
l am the:  Applicant/Inventor,  Assignee of record of the entire interest. See 37 CFR 3.71.  Stetement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)							
Signature Signature Date 0/8//0							
Name Steven A. McAuley	Telephone 71c3, 194, 2425						
Title and Company Assistant Secretary Parket (Cursif.							
NOTE. Signatures of all the inventors or assignees of record-of the Unities Interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.							
*Total of forms are submitted.							

This collection of information is required by 37 CFR 1.31, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE REGARDING CERTAIN PATENT MATTERS EFFECTIVE THROUGH: December 31, 2010

LIILCIIVL IIINOOGII. Decembei 51, 2010

I, Lawrence J. Knopf, as Senior Vice President and Deputy General Counsel of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Action Medical, Inc.; Advanced Stent Technologies, Inc.; AFx, Inc.; AMS Medinvent S.A.; BEI Medical Systems; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); BEI Medical Systems International, Inc.; Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Cupertino Corp.; Boston Scientific Ireland Limited; Boston Scientific Japan KK; Boston Scientific Limited; Boston Scientific Neuromodulation Corporation; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation; Cardiothoracic Systems, Inc.; Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A.; CryoCor, Inc.; CryoVascular Systems, Inc.; Embolic Protection, Inc.; Embro Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc.; EP Technologies, Inc.; Fidus Medical Technology Corporation; Guidant Corporation; Guidant Holdings, Inc.; Guidant Intercontinental Corporation; Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technologies; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Laboratoires Corvita S.A.R.L.; Meadox Medicals, Inc.; NAMIC Eireann Limited; NAMIC International, Inc.; Nilo Holding, S.A.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc.; Quanum Corporation; Radio Therapeutics Corporation; Remon Medical Technologies, Ltd.; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC; Scimed Life Systems, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; TriVascular, Inc.; and Vesica;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

	발매 발매 그리고 바다 모든 나를 보고 있다면 하는 그 그를 모르는데 그 그 그 그	Proceedings of the Control of the Co	그 하는 그래의 그 사이 그녀는 그러워 생활되게 하는데게 하는데 되는데	"这是一个一个是一个人,我们就是一个人的,这是不是什么。"
	Victoria Aguilera Poissant	Reg. No. 56,871	Albert K. Kau	Reg. No. 40,672
	Alana Bergman	Reg. No. 47,420	Philip H. Lee	Reg. No. 50,645
ċ	James R. Chiapetta		Kurt W. Lockwood	Reg. No. 40,704
	Sara J. Citrowske	Reg. No. 55,076	Jeffrey Z. Mann	Reg. No. 51,994
	Richard R. Clapp	Reg. No. 31,751	Steven A. McAuley	Reg. No. 46,084
	Jeffrey P. Cook	Reg. No. 48,649	Todd P. Messal	Reg. No. 42,883
	Luke R. Dohmen	Reg. No. 36,783	Tyler L. Nasiedlak	
	Peter J. Gafner	,Reg. No. 36,517	William J. Shaw	Reg. No. 43,111
3	Lori J. Heinrichs	Reg. No. 43,667		
2		<del></del> >		All Marketines (1986)

Lawrence J. Knopf, Senior Vice President and Deputy General Counsel

Date

COMMONWEALTH OF MASSACHUSETTS

COUNTY OF MIDDLESEX

) ss.

On this 23rd day of July before me personally appeared Lawrence J. Knopf to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.

Notary Public

Nona E Hurd NOTARY PUBLIC My commission expires Sept 18, 2009